• OPEN AN ACCOUNT
Indian Indices
Sensex
82,104.79 512.34
( 0.63%)
Global Indices
Nasdaq
51,667.44 -701.11
(-1.34%)
Dow Jones
7,446.91 -135.76
(-1.79%)
Hang Seng
59,680.29 -1,462.06
(-2.39%)
Nikkei 225
10,901.11 -1.45
(-0.01%)
Forex
USD-INR
93.92 0.20
(0.22%)
EUR-INR
104.00 -0.26
(-0.25%)
GBP-INR
124.47 -0.25
(-0.20%)
JPY-INR
0.59 0.00
(-0.08%)

EQUITY - MARKET SCREENER

Larsen & Toubro Ltd
Industry :  Engineering - Turnkey Services
BSE Code
ISIN Demat
Book Value()
500510
INE018A01030
559.0364408
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LT
36.5
569326.56
EPS(TTM)
Face Value()
Div & Yield %
113.35
2
0.92
 

Invagen Pharmaceuticals enters licensing agreement with Qilu
Sep 04,2026

Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co. (Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States.

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.